Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.
In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.
During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.
High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.
Adult patients with acute lymphoblastic leukemia who have relapsed following hematopoietic cell transplantation have experienced considerably improved survival benefits over the past few years, which may be due to an increased use of immunotherapy.
A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.
Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.